Adult: 10 mg once daily or 5 mg bid. Child: 2-12 years <30 kg: 5 mg once daily; >30 kg: 10 mg once daily. >12 years Same as adult dose.
10 mg every other day.
Severe: Initially, 10 mg every other day.
May be taken with or without food.
Severe hepatic and renal impairment. Children. Pregnancy and lactation.
Significant: Headache, somnolence, drowsiness, fatigue, nervousness. Cardiac disorders: Palpitation, tachycardia, hypotension. Gastrointestinal disorders: Dry mouth, abdominal pain, nausea, vomiting, diarrhoea, gastritis. General disorders and admin site conditions: Malaise. Hepatobiliary disorders: Jaundice, hepatitis, hepatic necrosis. Investigations: Elevated liver enzymes, weight gain. Metabolism and nutrition disorders: Increased appetite. Nervous system disorders: Dizziness. Skin and subcutaneous tissue disorders: Rash, alopecia.
Patient Counseling Information
This drug may cause dizziness, if affected, do not drive or operate machinery.
Symptoms: Somnolence, tachycardia, drowsiness, headache. Management: Symptomatic and supportive treatment. May administer activated charcoal and may perform gastric lavage.
May increase plasma concentrations with ketoconazole, fluconazole, erythromycin, clarithromycin, cimetidine.
Food delays time to peak plasma concentration and increases bioavailability. Increase risk of CNS depression with alcohol.
May diminish the wheal and flare reactions to skin test antigens.
Description: Loratadine, a piperidine derivative, is a long-acting, non-sedating antihistamine which selectively inhibits histamine H1-receptors on effector cells. Onset: 1-3 hours. Duration: >24 hours. Pharmacokinetics: Absorption: Rapidly and well absorbed from the gastrointestinal tract. Food delays time to peak plasma concentration and increases bioavailability. Time to peak plasma concentration: Approx 1-1.5 hours (loratadine); approx. 1.5-3.7 hours (desloratadine). Distribution: Enters breast milk. Volume of distribution: 119 L/kg. Plasma protein binding: Approx 97-99% (loratadine); approx 73-76% (desloratadine). Metabolism: Extensively undergoes first-pass metabolism in the liver via CYP2D6 and CYP3A4 to desloratadine as the active metabolite. Excretion: Via urine (40%); faeces (approx 40% as metabolites). Elimination half-life: 8.4 hours (loratadine); 28 hours (desloratadine).
Store between 20-25°C. Protect from heat, light and moisture.